These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 24198242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

  • 3. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
    Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A.
    J Clin Oncol; 2009 Aug 20; 27(24):3908-15. PubMed ID: 19620495
    [Abstract] [Full Text] [Related]

  • 4. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P.
    J Clin Oncol; 2014 Apr 01; 32(10):1050-7. PubMed ID: 24590635
    [Abstract] [Full Text] [Related]

  • 5. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.
    J Clin Oncol; 2012 Jul 20; 30(21):2585-92. PubMed ID: 22689807
    [Abstract] [Full Text] [Related]

  • 6. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.
    JAMA Oncol; 2016 Oct 01; 2(10):1287-1294. PubMed ID: 27281556
    [Abstract] [Full Text] [Related]

  • 7. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ.
    Clin Cancer Res; 2010 Mar 15; 16(6):1904-14. PubMed ID: 20215537
    [Abstract] [Full Text] [Related]

  • 8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 15; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 9. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M.
    J Clin Oncol; 2009 Nov 20; 27(33):5552-8. PubMed ID: 19858400
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
    Park JH, Kang MJ, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim SB.
    Cancer Chemother Pharmacol; 2016 Oct 20; 78(4):685-95. PubMed ID: 27491481
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
    Lancet Oncol; 2008 Jan 20; 9(1):23-8. PubMed ID: 18083065
    [Abstract] [Full Text] [Related]

  • 12. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.
    J Clin Oncol; 2008 Mar 01; 26(7):1059-65. PubMed ID: 18227529
    [Abstract] [Full Text] [Related]

  • 13. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y.
    Clin Breast Cancer; 2015 Jun 01; 15(3):204-11. PubMed ID: 25600243
    [Abstract] [Full Text] [Related]

  • 14. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
    Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ.
    Breast Cancer Res Treat; 2007 Mar 01; 102(1):43-9. PubMed ID: 16897431
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL, National Cancer Institute of Canada Clinical Trials Group MA.17.
    J Clin Oncol; 2007 May 20; 25(15):2006-11. PubMed ID: 17452676
    [Abstract] [Full Text] [Related]

  • 16. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW.
    Curr Med Res Opin; 2012 Aug 20; 28(8):1263-79. PubMed ID: 22738819
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H.
    J Clin Oncol; 2013 Jun 01; 31(16):1947-53. PubMed ID: 23509322
    [Abstract] [Full Text] [Related]

  • 18. Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
    Curran MP.
    Drugs; 2010 Jul 30; 70(11):1411-22. PubMed ID: 20614948
    [Abstract] [Full Text] [Related]

  • 19. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
    Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S.
    Oncologist; 2010 Jul 30; 15(2):122-9. PubMed ID: 20156908
    [Abstract] [Full Text] [Related]

  • 20. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT.
    Clin Cancer Res; 2008 Dec 01; 14(23):7861-70. PubMed ID: 19047115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.